

SCIENTIFIC PROGRAMME (AOGIN 2010)

Friday, March 26, 2010		
1800 hrs	<i>Inaugural Ceremony – Taj Palace Hotel, Durbar Hall</i> Chief Guest: Shri Ghulam Nabi Azad, Hon'ble Minister of Health & Family Welfare, Govt. of India	
	Keynote Address: Professor Keerti V. Shah, USA "Beyond the Nobel Prize – Reducing the burden of cervical cancer"	
Cultural Program and Welcome Reception		
Saturday, March 27, 2010		
	Hall A (Durbar Hall)	Hall B (Mumtaz Hall)
0800 -0830 hrs:	Presidential Lecture : Changing trends of surgery for cervical cancer: Jong Sup Park, Korea	
0830 -1030 hrs:	Session 1 – Plenary - Natural History and Epidemiology I-1.1. Natural history of HPV infections: epidemiological & clinical perspectives: R Sankaranarayanan, France I-1.2. Global HPV epidemiology update: Xavier Bosch, Spain I-1.3. Asia Oceania HPV Update: Ji-Hong Liu, China I-1.4. Burden of cervical cancer in Asia Oceania: A Nandakumar, India I-1.5. Male genital HPV infections: Suzanne Garland, Australia O-1.1. Population prevalence of high risk human papilloma virus (HPV) infection in semi-urban and rural areas adjoining Chennai, India: Malliga J. Subramaniam, India O-1.2. HPV genotyping and consequences for HPV vaccination in 500 healthy women attending a private woman's clinic in Tokyo – Sharon JB Hanley, Japan	Session 2 – Plenary - Eradication of Cervical Cancer: New Horizons I-2.1. Immune pathways relevant for high risk HPV infection & cervical carcinogenesis: Shubhda Chiplunkar, India I-2.2. Novel cellular/molecular mechanisms of HPV infections & cervical carcinogenesis - Role of epigenetics: Sharmila Sengupta, India I-2.3. Sequence variation within HPV16 isolates implicated in cervical cancer pathogenesis: Neeta Singh, India I-2.4. New molecular markers in prediction of high grade disease: Sandeep Mathur, India Novel profile active/therapeutic approaches for counter acting cervical carcinogenesis: I-2.5. Second generation vaccines - a suitable alternative?: Moushumi Bharadwaj, India I-2.6. Natural antiviral & immunomodulators: Bhudev C Das, India I-2.7. HPV and progression to cancer in the immunosuppressed: Priya Abraham, India
1030-1100 hrs:	Coffee Break	
1100-1200 hrs:	Session 3 – Plenary - Screening of Cervical Neoplasia I-3.1. Recent advances in cervical cancer prevention in low-and medium resource countries: R Sankaranarayanan, IARC, France I-3.2. START - UP program results: Jose Jeronimo, PATH, USA I-3.3. Self-sampling – A viable alternative? : Niharika Khanna, USA	Session 4 – Proffered Papers I (Basic Sciences: New Techniques and Molecular Markers) O-4.1. Assessment of a real-time computer-assistant imaging system for cervical cytology in China: Bin Yang, USA O-4.2. Interleucin-10-1082 G/A polymorphism in HPV related cervical lesions: Mary Clarisse Bozzetti, Brazil O-4.3. Comparing the Papanicolaou staining with a newer technique - Modified Ultra Fast Papanicolaou Staining (MUPS) in screening cervical cancer: Pushp Lata Sankhwar, India O-4.4. A new generation of cervical cancer detection? The power and promise of DNA methylation biomarker: Hung-Cheng Lai, Taiwan O-4.5. PCDH10 promoter methylation- a novel biomarker for cervical cancer detection: Deeksha Pandey, India O-4.6. Evaluation of the Digene HPV Genotyping Probeset Test (PS) relative to type-Specific qPCR: Ha Thanh Thai, USA

1200-1300 hrs:	<p>Session 5 – Plenary - Management of Cervical Neoplasia</p> <p>I-5.1. HPV positive test: What do you do?: Efen Domingo, Philippines</p> <p>I-5.2. CIN management options & post-treatment follow-up: Patrick Walker, UK</p> <p>I-5.3. Long term complications of cryotherapy and LEEP: Quek Swee Chong, Singapore</p>	<p>Session 6 – Proffered Papers II (HPV Prophylactic Vaccines: Basic and clinical , aspects)</p> <p>O-6.1. Baseline characteristics of women in Asia-Pacific region vaccinated with AS04-adjuvanted HPV-16/18 vaccine in the phase III PATRICIA trial: Unnop Jaisamrarn, Thailand</p> <p>O-6.2. Sustained immunogenicity and efficacy of HPV-16/18-adjuvanted vaccine up to 7.3 years: Cecilia Maria Roteli-Martins, Brazil</p> <p>O-6.3. Long-term persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years: Tino F. Schwarz, Germany</p> <p>O-6.4. Update on quadrivalent human papillomavirus [HPV] 6/11/16/18 vaccine clinical trial efficacy results: Suzanne Garland, Australia</p> <p>O-6.5. Quadrivalent HPV (types 6/11/16/18) vaccine: End-of-study efficacy against HPV6/11/16/18-related persistent infection and disease in women aged 24 to 45: Ricardo Manalastas, Philippines</p> <p>O-6.6. Monitoring HPV vaccination: The National HPV Vaccination Program Register, Australia: Dorota M Gertig, Australia</p>
1300-1400 hrs:	Lunch Break	
1400 -1500 hrs:	GSK Sponsored Post-Luncheon Symposium	
1500 -1530 hrs:	Coffee Break	
1530 -1700 hrs:	<p>Session 7 – Plenary - Cancer Treatment Updates</p> <p>I-7.1. Management of early stage cervical cancer – Outcomes of surgery and radiotherapy: Lynette Denny, South Africa</p> <p>I-7.2. Surgical Management of FIGO IB2 and IIB Cervical Cancer: Shingo Fujii, Japan</p> <p>I-7.3. Minimally Invasive Surgery in Gynaecologic Oncology: Alka Kriplani, India</p> <p>I-7.4. The place of chemotherapy in cervical cancer: Lalit Kumar, India</p> <p>I-7.5. Novel therapies for cervical cancer: TY Chu, Taiwan</p>	<p>Session 8 – IARC Symposium - Promising Strategies for Cervical Cancer Programs in Low Resource Countries</p> <p>I-8.1. Bangladesh VIA-based program: Ashrafun Nessa, Bangladesh</p> <p>I-8.2. The China experience on introducing population-based cervical cancer screening : You Lin Qiao, China</p> <p>I-8.3. Results from India: Sharmila Pimple, India</p> <p>I-8.4. Thailand Screen-and-Treat Program: Wachera Eamratsameekool, Thailand</p> <p>O-8.1. Using best practices for advocacy to strengthen a cervical cancer prevention program in the Philippines Cecilia Llave, Philippines</p> <p>O-8.2. Initial experience with HPV vaccine in Nepal: Veena Shrivastava, Nepal</p>
1900 -2200	Conference Banquet	
Sunday, March 28, 2010		
	Hall A (Durbar Hall)	Hall B (Mumtaz Hall)
0800-0900 hrs:	<p>Session 9 – Plenary - STIs and Neoplastic Diseases in the Lower Genital Tract</p> <p>I-9.1. The Role of HPV in VIN & VAIN: Xavier Bosch, Spain</p> <p>I-9.2. HPV and HIV infections: Isabelle Heard, France</p> <p>I-9.3. Syndromic management of STI's – The flip side: Neena Khanna, India</p> <p>I-9.4. Treatment of Genital Warts - Efficacy & Limitations: Christopher Fairley, Australia</p>	<p>Session 10 – Proffered Papers III (Cervical Screening and Colposcopy)</p> <p>O-10.1. Determinants of visual inspection of the cervix after acetic acid application (VIA) positivity in cervical cancer screening of women in a peri-urban area in Andhra Pradesh, India: Kalpana Betha, India</p> <p>O-10.2. VIA-VILI as routine gynecologic examination? Shalini Rajaram, India</p> <p>O-10.3. How to overcome the problem of unsatisfactory colposcopy? Vijay Zutshi, India</p> <p>O-10.4. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a pooled analysis</p>

		<p>of 18 population-based studies from China: Fang-Hui Zhao, China</p> <p>O-10.5. Evaluation Of The Cervista HPV Assay And Mass Spectroscopy For High-Risk HPV Compared To Hc-II ?" From The Shenccast II Trial: Hui Du, China</p> <p>O-10.6. Evaluation of the Cervista HPV assay and Liquid Based Cytology using the Thinprep Integrated Imager?" From the ShenCCAST II Trial: Jerome Leslie Belinson, USA</p>
0900-0930 hrs:	<p>Session 11 – Late Breaker Presentations</p> <p>O-11.1. A CAREHPV™ Reflex Test To Triage HPV+ women In economically constrained community screening programs: Paul S. Eder, USA</p> <p>O-11.2. Efficacy, immunogenicity and safety of HPV-16/18 AS04 adjuvanted vaccine in Japanese women: Final analysis at month 24: Ryo Konno, Japan</p> <p>O-11.3. Impact of a quadrivalent HPV 6/11/16/18 vaccine in women who have undergone definitive therapy: Suzanne Garland, Australia</p>	<p>Session 12 – Proffered Papers IV (Advocacy and Education)</p> <p>O-12.1. Assessment of the subject recruitment systems adopted in a beneficial Cervical Cancer Screening Trial (ShenCCAST II): Yun Chen, China</p> <p>O-12.2. It's a logistical nightmare! Recommendations for optimizing HPV school-based vaccination from Australia: Susan Rachel Skinner, Australia</p> <p>O-12.3. Healthy women project organized population based screening: Lakhbir Dhaliwal, India</p>
0930-1030 hrs:	<p>Session 13 – Plenary - New issues on HPV Vaccination</p> <p>I-13.1. Current evidence from prophylactic vaccines – Are we confused?: E H Tay, Singapore</p> <p>I-13.2. Vaccination for older women – Evidence and practice: Jeffrey Tan, Australia</p> <p>I-13.3. Therapeutic vaccines – Current status: Ian Frazer, Australia</p>	<p>Session 14 – Proffered Papers V (Cervical Screening and Management of CIN)</p> <p>O-14.1. Shenzhen Cervical Cancer Screening Study I (ShenCCAST I): Ruifang Wu, China</p> <p>O-14.2. Evaluation of the POI/NIH cervico-vaginal self-sampler for HPV- from the Shenccast II trial: Jerome Leslie Belinson, USA</p> <p>O-14.3. Trend of management of high grade CIN in a colposcopy clinic of Bangladesh: Ashrafun Nessa, Bangladesh</p> <p>O-14.4. Correlation of Human Papillomavirus DNA testing with residual disease in treated cases of Cervical Intraepithelial Neoplasia: Sunita Agarwal, India</p> <p>O-14.5. Evaluation of the conservative treatment effect of microinvasive cervical cancer by LLETZ: Tang Huiru, China</p> <p>O-14.6. Lessons from success and failure from cervical cancer screening in Japan: Ryo Konno, Japan</p>
1030-1100 hrs:	Coffee Break	
1100-1155 hrs:	<p>Session 15 – Plenary - Implementation of HPV Vaccination (PATH)</p> <p>I-15.1. Lessons from vaccine introduction in the developed world (Scotland): Heather Cubie, UK</p> <p>I-15.2. Lessons from vaccine introduction in developing countries (India, Vietnam): Aisha O Jumaan, PATH, USA</p> <p>I-15.3. New tools for comprehensive cervical cancer prevention planning: Scott Wittet, PATH, USA</p>	<p>Session 16 – Qiagen Sponsored Satellite Symposium</p> <p>I-16.1. Can HPV be the sole primary screening test?: Jack Cuzick, UK</p> <p>I-16.2. HPV screening – New data & new algorithms: Attila Lorincz, UK</p> <p>I-16.3. The accuracy of colposcopy and its appropriate use in cervical cancer screening trials: Jerome Belinson, China</p>
1200-1300 hrs:	MSD Sponsored Pre-Luncheon Symposium	
1300-1400	Lunch	

hrs:		
1400-1500 hrs:	<p>Session 17 – Plenary - AOGIN Education Session</p> <p>I-17.1. Can cervical cancer be controlled in the developing world?: Lynette Denny, South Africa</p> <p>I-17.2. How to educate the public on HPV and cervical cancer prevention: Hextan Ngan, Hong Kong</p> <p>I-17.3. CIN 1: When should it be treated?: Shalini Rajaram, India</p>	<p>Session 18 – Proffered Papers VI (STIs)</p> <p>O-18.1. Incidence of Herpes Simplex Virus Type 2 in young reproductive age women in Mysore, India: Purnima Madhivanan, India</p> <p>O-18.2. Vaginal douching facilitates infection of human papillomavirus and non-regression of its cervical intraepithelial lesion: Tang-Yuan Chu, Taiwan</p> <p>O-18.3. HPV detection by using urine sample compared with cervical smear in women of reproductive age group with or without high risk factors: Jyoti Malik, India</p> <p>O-18.4. High risk HPV DNA is a useful biological marker for diagnosis of early cervical cancer in HIV sero-positive women: Veena Acharya, India</p> <p>O-18.5. The behavior of CIN in HIV seropositive women: Seema Sharma, India</p>
1500-1530 hrs:	Coffee Break	
1530-1615 hrs:	<p>Session 19 – Debates</p> <p>1. HPV vaccination of older women is preferable to screening in developing countries <i>For</i> – Partha Basu, India <i>Against</i> – Elizabeth Vallikad, India</p> <p>2. HPV test should be the sole primary screening test <i>For</i> – Rama Joshi, India <i>Against</i> – Usha Rani Poli, India</p>	<p>Session 20 – Proffered Video Session</p> <p>V-20.1. Laparoscopic pelvic anatomy related to radical hysterectomy: Pradeep Garg, India</p> <p>V-20.2. Microcolpohysteroscopy in evaluation of cervical pathology: Meena Naik, India</p> <p>V-20.3. Bowen's disease of vulva- Timing and technique of vulvectomy? Anju Rajesh Hajari, India</p> <p>V-20.4. Scott Wittet, PATH, USA</p>
1615-1645 hrs:	<p>Presentation of AOGIN Guidelines on Cervical Cancer Prevention Presenter: Hextan Ngan, Hong Kong</p>	
1630-1715 hrs:	<p>AOGIN General Assembly & Closing Ceremony: Address by Incoming President Professor Hextan Ngan Prize distribution Announcement of AOGIN 2012 venue and Close of Conference</p>	

4th Biennial Conference of Asia Oceania research organization on Genital Infections and Neoplasia

(AOGIN 2010)

COLPOSCOPY AND HANDS-ON LEEP

Date: March 26, 2010,
Time: 8.00 a.m.- 4 p.m.
Venue: Maulana Azad Medical College, New Delhi.

CYTOLOGY AND HPV TESTING

Date: March 26, 2010,
Time: 8.00 a.m. - 4 p.m.
Venue: The Taj Palace Hotel, New Delhi.

ONCOSURGICAL VIDEO WORKSHOP

Date: March 26 2010,
Time: 8.00 a.m. - 4 p.m.
Venue: The Taj Palace Hotel, New Delhi.

WHO WEBCAST TO ASIA-OCEANIA REGION ON HPV VACCINATION

Date: March 26 2010,
Time: 8.00 a.m. – 9.30 a.m.
Venue: The Taj Palace Hotel, New Delhi.

QUIZ ON LOWER GENITAL TRACT INFECTIONS AND NEOPLASIA

Date: March 26 2010,
Time: 4.00 p.m. – 5.00 p.m.
Venue: The Taj Palace Hotel, New Delhi.

PRE-CONGRESS COLPOSCOPY AND HANDS-ON LEEP WORKSHOP

co-sponsored by the International Federation of Cervical Pathology and Colposcopy (IFCPC)

March 26, 2010, 8.00 a.m.- 4 p.m.

Venue: Maulana Azad Medical College, New Delhi

Organising Chairperson: Neerja Bhatla

Coordinators: Quek Swee Chong, Vijay Zutshi

Programme

0800-0830 hrs : REGISTRATION & INAUGURATION

0830-1030 hrs : COLPOSCOPY COURSE

1. Anatomical and histological basis of colposcopy - 20 mins - *Patrick Walker, UK*
2. Colposcopy of the normal cervix - 20 mins - *Albert Singer, UK*
3. Colposcopy of the abnormal cervix - 20 mins - *Narendra Pisal, UK*
4. Pitfalls of colposcopy - 20 mins - *Quek Swee Chong, Singapore*
5. The role of cold coagulation in the treatment of CIN - 20 mins - *R Sankaranarayanan, France*

1030 - 1100 hrs - COFFEE BREAK

1100-1300 hrs : PRACTICAL CASE DEMONSTRATION (LIVE) : *Patrick Walker, Quek Swee Chong, Narendra Pisal, Jeffrey Tan, R Sankaranarayanan*

Coordinators: Partha Basu, Saritha Shamsunder, Neha Gami

1. Colposcopy
2. Cryotherapy
3. Cold Coagulation
4. LEEP

1300 - 1400 hrs - LUNCH

1400-1600 hrs : Breakout Groups

(I) Practical Hands-on cryotherapy and LEEP exercises (six stations):

60 mins - *Quek Swee Chong, Vijay Zutshi, Partha Basu, Raksha Arora, Gauri Gandhi, Usha Rani Poli, Esmey PO, Sharmila Pimple, Asha Jain, Kavita N. Singh, Uma Singh, Bharti Bharani, Sumita Mehta, Poonam Sachdeva*

(II) Interactive Case Discussions - 60 mins - *Albert Singer, Narendra Pisal, Swaraj Batra*

1600 hrs - CLOSE OF WORKSHOP

1600 - 1700 hrs - TRAINING OF TRAINERS

(By invitation only)

PRE-CONGRESS WORKSHOP ON CYTOLOGY & HPV TESTING

March 26, 2010, Time: 8.00 a.m. - 4 p.m.

Venue: The Taj Palace Hotel, New Delhi

Organising Chairperson: Neerja Bhatla
Coordinators: Kusum Verma, Annie Cheung

Programme

0800-0930 hrs : REGISTRATION

[0800-0930 hrs : WHO WEBCAST TO ASIA_OCEANIA REGION ON HPV VACCINATION]

0930-1030 hrs : CYTOPATHOLOGY

- | | |
|--|-------------------------------------|
| 1. Cytology for screening: scope and limitations | <i>Kusum Verma, India</i> |
| 2. HPV/Pap triage in routine primary cervical cancer screening | <i>Kelvin YK Chan, Hong Kong</i> |
| 3. Liquid based cytology and reflex HPV testing | <i>Venkateswaran K. Iyer, India</i> |

1030 -1100 hrs - TEA/COFFEE BREAK

1100-1300 hrs: HPV DIAGNOSTICS

- | | |
|--|--------------------------------|
| 4. HPV DNA tests vs PCR: Role of HPV Genotyping | <i>Lalit Dar, India</i> |
| 5. Role of HPV m-RNA testing | <i>Sam Ratnam, Canada</i> |
| 6. Biomarkers: Role of p16 and other cell cycle markers in triage | <i>Annie Cheung, Hong Kong</i> |
| 7. Pitfalls of HPV testing and How to run a QA program: WHO Labnet | <i>Heather Cubie, UK</i> |

1300-1400 hrs – LUNCH

1400-1500 hrs – HISTOPATHOLOGY

- | | |
|---|---------------------------------|
| 8. CIN: conventional vs. two-tiered reporting | <i>Sandeep K. Mathur, India</i> |
| 9. HPV carcinogenesis and glandular lesions | <i>Arvind Rajwanshi, India</i> |
| 10. Pre-neoplastic lesions of Vulva & Vagina | <i>Manoj K. Singh, India</i> |
| 11. Role of immunohistochemistry in problematic cervical biopsies | <i>TBA - Annie</i> |

1500-1530 hrs - TEA/COFFEE BREAK

1530-1600 hrs – SCREENING IN SPECIAL SITUATIONS

- | | |
|--|---------------------------|
| 12. Screening in low resource settings | <i>Lynette Denny, RSA</i> |
| 13. Screening in the post vaccine era | <i>Attila Lorincz, UK</i> |

1600 hrs – CLOSING REMARKS

PRE-CONGRESS ONCOSURGICAL VIDEO WORKSHOP

co-sponsored by IGCS

March 26 2010, Time: 8.00 a.m. - 4 p.m.

Venue: The Taj Palace Hotel, New Delhi

Organising Chairperson: Neerja Bhatla

Coordinators: Eng Hseon Tay, Shalini Rajaram

Programme

0800-0830 hrs : Registration

0830-1030 hrs : Session I

Introduction to Objectives of Workshop, Understanding
surgical anatomy and pelvic spaces
Abdominal Radical Hysterectomy
Nerve sparing radical hysterectomy
Laparoscopic radical hysterectomy

EH Tay, Singapore
EH Tay, Singapore
Shingo Fujii, Japan
Alka Kriplani, India

1030 -1100 hrs - COFFEE BREAK

1100-1300 hrs: Session II

Vaginal Radical Hysterectomy
Extraperitoneal lymphadenectomy
Vaginal Radical trachelectomy
LEEP with Harmonic Scalpel
Single port laparoscopic radical hysterectomy; Ovarian transposition

KD Biswas, India
Ranajit Mandal, India
Vito Chiantera, Germany
Ryo Konno, Japan
Shailesh Puntambekar, India

1300-1400 hrs - LUNCH

1400-1500 hrs: Session III

Sentinel node evaluation in cervical & vulvar cancers
Radical vulvectomy with groin dissection
Laparoscopic groin dissection
IMRT

SP Somasekhar, India
K. Uma Devi, India
Rupinder Sekhon, India
DN Sharma, India

1500-1530 hrs - COFFEE BREAK

1530 -1600 hrs: Session IV

Posterior Pelvic exenteration & Anovulvectomy
Robotic radical hysterectomy

Kavita Singh, UK
Hextan Ngan, Hong Kong

1600 hrs - CLOSE OF WORKSHOP

Shalini Rajaram

PRE-CONGRESS WEBCAST ON HPV VACCINATION

co-sponsored by WHO

March 26 2010, Time: 8.00 a.m. – 9.30 a.m.

Venue: The Taj Palace Hotel, New Delhi

0800-0930 hrs : WHO WEBCAST TO ASIA_OCEANIA REGION

Moderator: Dr. Neerja Bhatla

Panelists: You Lin Qiao, Suzanne Garland, Partha Basu, Manju Rani.

Panel discussion, focused on the Asia-Pacific world region, with the following objectives:

1. To present WHO recommendations for HPV vaccines.
2. To discuss the feasibility and challenges of integrating HPV vaccines into existing cervical cancer prevention strategies and adolescent health programs in the Asia-Pacific region.
3. To review data about HPV vaccine safety in this region and globally, to review safety monitoring systems, and to discuss effective ways to address concerns about vaccine safety - .
4. To discuss monitoring of outcomes for different cervical cancer prevention strategies including vaccination, in this region.
5. To discuss the efficacy, feasibility, and cost consideration of vaccinating boys against HPV.

QUIZ ON LOWER GENITAL TRACT INFECTIONS AND NEOPLASIA

March 26 2010, Time: 4.00 p.m. – 5.30 p.m.

Venue: The Taj Palace Hotel, New Delhi

Quiz Masters: Aruna Batra, Shalini Rajaram, Sumita Mehta